Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Open-Label, Multicenter, Platform Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors

NCT04931342 is registered in ClinicalTrials.gov with Hoffmann-La Roche as lead sponsor.

NCT NCT04931342
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04931342 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Open-Label, Multicenter, Platform Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors
Lead sponsor
Hoffmann-La Roche
Phase
Phase 2
Overall status
Active, not recruiting
Start date
October 7, 2021
Completion date
May 30, 2028
Enrollment
176 (actual)
Sites
41

Conditions

As the registry lists them; a condition with its own page is linked.

ovarian cancer